Metriopharm Ag

Athenion Ag

Immunologik Gmbh

Jörg Von Wegerer

Wolfgang Brysch

Josef Breu

Thomas Martin

Ingo Saar

Beate Ludescher

Juliane Fleissner

Astrid Kaiser

Michael Niedermaier

Maliha Shah

Ulrich Schubert

Christian Setz

David Kosel

Claudia Van Laak

Ekkehard Brysch

Sara Schumann

Petra Schulz

The present invention relates to a method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione or salts thereof, to the solubilisate produced by this method and respective uses in pharmaceutical dosage forms. A phosphatidylcholine-based solubilization method is disclosed.

Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione

The present invention relates to a method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents, to the solubilisate produced by this method and respective uses as a dietary supplement or pharmaceutical dosage form. A phosphatidylcholine-based solubilization method is disclosed.

Method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents

The present invention relates to a method for solubilizing poorly water-soluble organic cosmetic agents, to the solubilisate and cosmetic preparations produced by this method and respective uses of the solubilisate in cosmetic preparations. A phosphatidylcholine-based solubilization method is disclosed.

Method for solubilizing poorly water-soluble cosmetic agents

A new method for producing a crystalline form of 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) is provided. Advantageous uses for this crystalline form as a detecting agent or as an agent for forensic purposes are disclosed, as well a pharmaceutical composition containing said crystalline form.

Methhod for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione

A new crystalline form of 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) is provided. Advantageous uses for this crystalline form as a detecting agent or as an agent for forensic purposes are disclosed, as well a pharmaceutical composition containing said crystalline form.

Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione

The invention relates to 5-amino-2,3-dihydro-1,4-phthalazinedione or related compounds, compositions or combinations thereof, for use in the treatment of chronic progressive multiple sclerosis, in particular primary and secondary progressive multiple sclerosis. The invention in particular relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes.

Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis

The invention relates to pyridine-3,5-bis-thiocyanates which are new active substances for the treatment and prevention of retroviral infections and secondary diseases thereof, in particular HIV infections and AIDS, from the group of deubiquitinase inhibitors. Administration of the compounds of the invention increases the immunogenicity of viral proteins and thus the antiviral response.

Agents for the treatment of retroviral infectious diseases

The invention relates to the provision of a new crystalline form for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium, the use of this form for medical purposes, methods for producing the crystalline form according to the invention, as well as pharmaceutical preparations comprising said form.

Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form

Growing community of inventors

Berlin, Germany

Jörg Von Wegerer